There are 2934 resources available
Making fatigue visible: Results of the Lymphoma Coalition 2018 survey
Presenter: Guy Bouguet
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Tackling the many factors that contribute to fatigue
Presenter: Matti Aapro
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Is more research needed to support the integration of exercise into the standard health basket for cancer care?
Presenter: Joachim Wiskemann
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Metastatic gastro-oesophageal adenocarcinoma
Presenter: Salah-Eddin Al-Batran
Session: ESMO Colloquium supported by Lilly Oncology - Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?
Resources:
Slides
Webcast
Metastatic colorectal cancer
Presenter: Michel Ducreux
Session: ESMO Colloquium supported by Lilly Oncology - Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?
Resources:
Slides
Webcast
Unresectable or relapsed hepato-cellular carcinomas
Presenter: Jean-Luc Raoul
Session: ESMO Colloquium supported by Lilly Oncology - Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?
Resources:
Slides
Webcast
Are FLT3 Mutated AML a special entity?
Presenter: Gert Ossenkoppele
Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Resources:
Slides
Webcast
Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML
Presenter: Lars Bullinger
Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Resources:
Slides
Webcast
Recent results with FLT3 Inhibitors in FLT3-ITD positive Relapsed/Refractory AML and future development
Presenter: Jorge Cortes
Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Resources:
Slides
Webcast
Introduction
Presenter: Bernard Escudier
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast